Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $74.2 million.

  • Viridian Therapeutics, Inc.\DE's Total Liabilities rose 1516.05% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 1516.05%. This contributed to the annual value of $70.8 million for FY2024, which is 4620.06% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Total Liabilities of $74.2 million as of Q3 2025, which was up 1516.05% from $67.2 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Liabilities peaked at $74.2 million during Q3 2025, and registered a low of $16.0 million during Q4 2021.
  • Moreover, its 5-year median value for Total Liabilities was $40.0 million (2022), whereas its average is $41.4 million.
  • Data for Viridian Therapeutics, Inc.\DE's Total Liabilities shows a peak YoY increase of 15027.82% (in 2022) and a maximum YoY decrease of 184.75% (in 2022) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Liabilities (Quarter) stood at $16.0 million in 2021, then surged by 150.28% to $40.0 million in 2022, then grew by 20.92% to $48.4 million in 2023, then surged by 46.2% to $70.8 million in 2024, then rose by 4.81% to $74.2 million in 2025.
  • Its last three reported values are $74.2 million in Q3 2025, $67.2 million for Q2 2025, and $56.5 million during Q1 2025.